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Abstract
Hepatitis B virus (HBV) infection and aflatoxin B1 (AFB1) exposure have been  
recognized as independent risk factors for the occurrence and exacerbation of  
hepatic steatosis but their combined impacts and the potential mechanisms remain 
to be further elucidated. Here, we showed that exposure to AFB1 impaired mito‐
chondrial dynamics and increased intracellular lipid droplets (LDs) in the liver of 
HBV‐transgenic mice in vivo and the hepatitis B virus X protein (HBx)‐expressing 
human hepatocytes both ex vivo and in vitro. HBx combined with AFB1 exposure 
also up‐regulated receptor interaction protein 1 (RIP1), receptor interaction protein 
3 (RIP3) and activated mixed lineage kinase domain like protein (MLKL), providing 
evidence of necrosome formation in the hepatocytes. The shift of the mitochondrial 
dynamics towards imbalance of fission and fusion was rescued when MLKL was 
inhibited in the HBx and AFB1 co‐treated hepatocytes. Most importantly, based on 
siRNA or CRISPR/Cas9 system, we found that the combination of HBx and AFB1 ex‐
posure increased cyclooxygenase‐2 (COX‐2) to mediate up‐regulation of RIP3 and 
dynamin‐related protein 1 (Drp1), which in turn promoted location of RIP3‐MLKL 
necrosome on mitochondria, subsequently exacerbated steatosis in hepatocytes. 
Taken together, these findings advance the understanding of mechanism associated 
with HBx and AFB1‐induced hepatic necrosome formation, mitochondrial dysfunc‐
tion and steatosis and make COX‐2 a good candidate for treatment.
K E Y W O R D S
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1  | INTRODUC TION
Hepatic steatosis, characterized by aberrant accumulation of lipid 
droplets (LDs), is suggested to be a prerequisite and cofactor for 
fatty liver disease and subsequent hepatic injury, such as inflam‐
mation, fibrosis, cirrhosis and hepatocellular carcinoma (HCC). In 
addition to the genetic and diet‐related factors, multiple epidemic 
studies suggested that hepatic steatosis was common in patient 
with chronic hepatitis B virus (HBV) infection.1 Hepatitis B virus 
X protein (HBx) is a multifunctional protein encoded by HBV ge‐
nome. It was reported that HBx trigged lipid accumulation in he‐
patocytes by increasing de novo lipogenesis and fatty acid (FA) 
uptake.2,3 However, there was a cross‐sectional population study in 
Hong Kong demonstrated that HBV infection was associated with 
a lower prevalence of non‐alcoholic fatty liver disease (NAFLD) and 
hypertriglyceridemia.4 This observation agreed with a prior data 
from Taiwan indicating that HBV‐infected patients had reduced 
serum triglyceride (TG).5 Whether HBV infection correlated with 
the development of hepatic steatosis is still controversial, and the 
role of HBx in it remains to be elucidated. Apart from HBV, the liver 
is a target organ of aflatoxin B1 (AFB1), one of mycotoxin found 
in the human foods. Exposure to AFB1 had been shown to affect 
some pathogenic events implicated in hepatic lipid homoeostasis. 
For example, exposure to 0.5 and 1 mg/kg of AFB1 for 7 days in‐
duced liver damage and dysregulation of genes associated with lipid 
metabolism in rats.6 Notably, HBV‐infected patients would be more 
susceptible to liver injury induced by AFB1.7 However, just one 
study in zebrafish showed that combination of HBx and AFB1 pro‐
moted hepatic steatosis and increased the expression of lipogenic 
factors and genes related to lipid metabolism yet.8 It is necessary to 
further determine the combined impact of HBx and AFB1 exposure 
on hepatic lipid homoeostasis and the potential mechanisms.
Increasing number of studies suggested that alterations of mi‐
tochondrial energetic metabolism were the initiating event in the 
development and progression of hepatic steatosis.9 Thus, fatty liver 
disease has been considered as a mitochondrial related disease.10 
Moreover, mitochondria are considered to be one of cell death exec‐
utor and several pathways of programmed cell death are involved in 
regulating liver homoeostasis.11 Necroptosis, a mode of programmed 
cell death, is involved in the development of NAFLD.12 Although ab‐
errant mitochondrial dynamics and function were served as crucial 
pathophysiological factors in HBV‐infected hepatocytes13 and AFB1 
could also impair mitochondrial functions,14 study addressing the 
interactive relations of mitochondrial dysfunction and necroptosis 
in AFB1 exposure and/or HBV infection‐driven hepatic steatosis is 
lacking up to now.
Interestingly, our previous study showed that cyclooxygen‐
ase‐2 (COX‐2) promoted mitochondrial translocation of dynamin‐
related protein 1 (Drp1), an important mediator of mitochondrial 
fission, resulting in a higher percentage of fragmented mito‐
chondria in the cancer stem cells.15 In spite of the extremely low 
expression in the liver, COX‐2 can be induced by a variety of extra‐
cellular and intracellular stimuli, including reactive oxygen species, 
chemicals and viral infections.16 Higher expression of COX‐2 was 
observed in patients with clinical diagnosis of NAFLD than those 
in subjects with histologically normal liver.17 More importantly, 
knocking down of COX‐2 with small interfering RNA for prosta‐
glandin‐endoperoxide synthase 2 gene (PTGS2) encoding COX‐2 
(siPTGS2) or selective COX‐2 inhibitor celecoxib ameliorated ste‐
atosis in palmitate‐treated hepatocytes and in liver of high‐fat diet‐
fed rats,18 highlighting that COX‐2 should be a key regulator in the 
development of NAFLD. As we known, higher expression of COX‐2 
was shown in the hepatocytes of HBV‐infected patients, even in 
patients with antiviral therapies.19 HBx decreased mitochondrial 
membrane potential and ATP, and up‐regulated COX‐2 in vitro.20 
Moreover, the expression of COX‐2 was also increased in the liver 
of AFB1‐treated rats and chicken.21,22 Therefore, there seemed to 
be a close, yet not totally understood, and complex interaction 
among COX‐2, mitochondrial dysfunction, necrosome formation 
and lipid accumulation in hepatocytes co‐exposed to HBx and 
AFB1. And the aim of this study was to figure out whether HBx 
and AFB1 could act in concert to activate COX‐2, subsequently 
alter mitochondrial dynamics and facilitate necrosome formation, 
which ultimately trigger hepatic steatosis.
2  | MATERIAL S AND METHODS
2.1 | Cell culture and treatment
Three HBx‐expressing cell lines including HepG2.2.15 cells integrat‐
ing two head‐to‐tail copies of the HBV genome, HBx expressing 
HepG2 cells (HepG2‐Tet‐ON‐HBx) and differentiated HepaRG cells 
were selected and constructed (Supporting information: Material and 
methods).23 All these stable cell lines expressing HBx were treated 
with 1 μmol/L of AFB1 (Sigma‐Aldrich, MO) for 48 or 72 hours. 
AFB1 was dissolved in DMSO. For COX‐2 and Drp1 knockdown, the 
cells were transfected with 50 nmol/L annealed double‐stranded 
siPTGS2 and siRNA for dynamin 1 like gene (DNM1L) encoding 
Drp1 (siDNM1L) (Ribobio, Guangzhou, China) using Lipofectamine® 
2000 (Invitrogen, CA), respectively. COX‐2 knockdown cell line was 
also generated by CRISPR/Cas9 systems (Supporting information: 
Material and methods).
2.2 | Animals and treatment
All of the animal experiments were performed in accordance with the 
guidelines of the Xiamen University Institutional Committee for the 
Care and Use of Laboratory Animals (no. XMULAC20140033). Mice 
were housed under specific pathogen‐free conditions and had ad libi‐
tum access to food and water. The human‐liver‐chimeric (HLC) mice for 
HBV infection were constructed through transplantation of primary 
human hepatocytes (PHHs) into Fah−/−/Rag2−/−/Il2rg−/− (FRG) male mice 
according to Azuma's methods.24 FRG male mice were infected with 
HBV derived from the supernatant of HepaAD38 cells for 6 weeks. 
Then, PHHs were isolated from the mice and exposed to 1 μmol/L 
of AFB1 for 48 or 72 hours. The HBV‐transgenic (HBV‐Tg) mice were 
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produced via the microinjection of pAAV/HBV1.2 (genotype Ae) into 
the embryos of male C57BL/6 mice. Male HBV‐Tg and C57BL/6 mice 
were administered peanut oil or 5 mg/kg of AFB1 dissolved in peanut 
oil by intraperitoneal injection on the first, fourth and seventh day for 
a total three injections.
2.3 | Gene expression omnibus (GEO) data analysis
Gene expression data of HBV‐infected patients were searched from 
GEO database (http://www.ncbi.nlm.nih.gov/geo/). The relative 
gene expressions of DNM1L, PTGS2 and MLKL were analysed as pre‐
viously described.15 Correlations between the expression of DNM1L 
and PTGS2, as well as PTGS2 and MLKL, were evaluated by Pearson's 
correlation analysis (SPSS, IL).
2.4 | Immunofluorescence (IF) and 
immunohistochemistry (IHC) analysis
For mitochondria morphology, the cells were incubated with 
100 nmol/L MitoTracker Red (Thermo Scientific, MA) for 30 min 
at 37°C. Fluorescence images of cells were obtained with a laser‐
scanning confocal microscope (Zeiss LSM 780, Jena, Germany). 
Mitochondrial morphological characteristics were quantified by the 
mitochondrial fragmentation counts as described previously.15 For 
IF, the cells were fixed in 4% paraformaldehyde and permeabilized 
with 0.5% Triton X‐100. Then the cells were blocked with 1% bovine 
serum albumin (BSA) and incubated with corresponding primary anti‐
bodies. Finally, the cells were incubated with secondary antibody and 
were imaged using laser‐scanning confocal microscope (Leika SP8, 
Wetzlar, Germany). Quantification of co‐localization was analysed by 
Image Pro Plus (IPP) version 6.0 software (MD, USA). For IHC, liver 
sections were stained with antibodies against HBx, COX‐2, RIP3 and 
p‐Drp1Ser616. All IHC images were examined under an upright light 
microscope (Nikon, Tokyo, Japan). The information of antibodies was 
described in the Supporting information: Material and methods.
2.5 | Proximity ligation assay (PLA)
The protein interaction between COX‐2 and RIP3 was determined by 
PLA using a Duolink® In Situ Detection Reagents (Sigma‐Aldrich) as 
previously described (Supporting information: Material and methods).15
2.6 | Co‐immunoprecipitation (Co‐IP)
HepG2‐Tet‐ON‐HBx cells were lysed with Nonidet P 40 (NP40) lysis 
buffer (Sigma‐Aldrich) and the whole cell extracts were collected. To 
precipitate the target protein, the cell lysates were incubated with 
SureBead (BioRad, CA) previously coated with anti‐COX‐2 antibody 
at room temperature for 1 hour. After the washing steps with PBS 
supplemented with 0.1% Tween 20, the binding proteins on the 
beads were eluted with 1× Sodium dodecyl dulfonate (SDS) buffer 
by 5‐min boiling. Eluted proteins were analysed by Western blot.
2.7 | Lipid index assays
The liver sections of mice were stained by Oil‐Red‐O (Jiancheng, 
Nanjing, China) to visualize LDs and the quantification was per‐
formed using IPP 6.0 software. The lipid content in cultured cells 
were also visualized and quantified using Oil‐Red‐O staining. In 
addition, lipids in the liver of mice were extracted and the hepatic 
TG and total cholesterol (TC) were measured using commercial kits 
(Jiancheng) according to the manufacturer's instructions.
2.8 | Western blot analysis
The livers and the cells were harvested and lysed using radio im‐
munoprecipitation assay (RIPA) buffer (Beyotime, Jiangsu, China) or 
1× SDS‐PAGE loading buffer. A mitochondrial isolation kit (EnzoLife, 
PA) were used to separate mitochondrial and cytosolic fractions. The 
protein concentrations were measured using BCA protein assay kit 
(Beyotime). For western blots, equal amounts of protein were sub‐
jected to gel electrophoresis, transferred to polyvinylidene fluoride 
(PVDF) membranes, and blocked with 5% skimmed milk before being 
incubated with primary antibodies (Supporting information: Material 
and methods). Then, the membranes were incubated with secondary 
antibodies and were visualized using the ECL‐Plus chemilumines‐
cence reagent (Advansta, CA, USA).
2.9 | RNA extraction and quantity real‐time PCR 
(qRT‐PCR)
Total RNA was extracted using TRIzol reagent (Takara, Osaka, Japan) 
and was reverse transcribed with Prime ScriptTM RT reagent kit 
(Takara). qRT‐PCR was then performed with SYBR® Premix Ex Taq™ 
II Kit (Takara) by CFX96 TouchTM Detection System (Bio‐Rad, CA). The 
primer sequences were listed in Supporting information: Table S1.
2.10 | Statistics
All data were expressed as the mean ± standard deviation (SD). All 
statistical analyses were conducted with SPSS software v.16.0. The 
differences in data measurements among the groups were analysed in‐
itially by a homogeneity test of variances, and then, either an unpaired 
Student's t test or one‐way ANOVA was performed under equivalent 
conditions. Pearson's correlation analysis was conducted for variables 
correlation. P < 0.05 was considered to be statistically significant.
3  | RESULTS
3.1 | Exposure to AFB1 exacerbated lipid droplets 
(LDs) accumulation in the liver of HBV‐Tg mice and 
HBx‐expressing hepatocytes
Based on the Oil‐Red‐O staining, Figure 1A showed that the 
amount of LDs was modestly increased in the liver tissues of 
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HBV‐Tg mice compared with those in wildtype (WT) mice; and 
significantly higher levels of LDs were observed in the liver of 
HBV‐Tg mice exposed to AFB1 than those in the unexposed 
HBV‐Tg mice. Meanwhile, hepatic TG and TC contents were 
increased in the AFB1‐exposed WT mice, the HBV‐Tg mice, as 
well as the AFB1‐exposed HBV‐Tg mice compared with cor‐
responding controls (Figure 1B, C). Besides animal models, 
human hepatocytes are the natural target of HBV infection. 
HLC mice for HBV infection were constructed and the PHHs 
were exposed to AFB1 (Supporting information: Figure S1). 
Figure 1D showed that LDs were increased in AFB1‐exposed 
PHHs from HLC mice compared with unexposed PHHs, no mat‐
ter whether infected HBV. The highest amounts of LDs were 
observed in the AFB1‐exposed‐PHHs from HBV‐infected HLC 
mice (Figure 1D). Consistent with the in vivo and ex vivo re‐
sults, LDs were increased in the HepG2.2.15 cells constitu‐
tively replicating HBV, no matter whether exposed to AFB1 
(Figure 1E). After exposed to AFB1, LDs were significantly in‐
creased in both the HepG2‐Tet‐ON‐HBx cells (Figure 1F) and 
the differentiated HepaRG cells (Figure 1G). Taken together, 
HBx combined with AFB1 exposure triggered LDs accumula‐
tion in the hepatocytes.
F I G U R E  1   Exposure to aflatoxin B1 (AFB1) exacerbated lipid droplet (LD) accumulation in the liver of HBV‐Tg mice and hepatitis B 
virus X protein (HBx)‐expressing hepatocytes. A‐C, HBV‐Tg or WT mice were treated with AFB1 or vehicle (peanut oil) every 3 days for 
1 week. Representative images and spectrophotometric quantification of LDs in liver section stained with Oil‐Red‐O (A). Levels of hepatic 
TC (B) and TG (C). D, Representative Oil‐Red‐O staining images and spectrophotometric quantification of LDs in PHHs ex vivo. PHHs were 
isolated from the HLC mice with (HLC‐HBV(+)) or without (HLC‐HBV(‐)) HBV infection and exposed to 1 μmol/L of AFB1 or DMSO for 72 h. 
E‐G, 1 μg/mL of DOX were used to stimulate HBx expression. Differentiated HepaRG cells were transfected with pcDNA3.1‐HBX (1 μg/
mL) to induce HBx expression. Cells were exposed to 1 μmol/L of AFB1 or DMSO for 72 h. Representative images and spectrophotometric 
quantification of LDs in HepG2.2.15 cells (E), HepG2‐Tet‐ON‐HBx cells (F) and differentiated HepaRG cells (G). Scale bar represents 10 μm. 
Data were represented by mean ± SD. n = 3. *P < 0.05 compared with unexposed cells or WT mice. #P < 0.05 compared with HBx‐expressing 
cells or HBV‐Tg mice. †P < 0.05 compared with AFB1‐exposed cells or AFB1‐exposed WT mice
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3.2 | Drp1‐dependent mitochondrial dynamics 
abnormalities regulated HBx and AFB1‐induced 
hepatic steatosis
Given that mitochondrial dysfunction is a key mediator of hepatic lipid 
metabolism, the impact of HBx and AFB1 on mitochondrial morphol‐
ogy and dynamics was investigated. MitoTracker staining showed 
that the mitochondrial network was broken down and fragmented 
into short rods or spheres in HepG2‐Tet‐ON‐HBx cells when HBx 
were switched on by DOX (Figure 2A,B). Mitochondrial fragmenta‐
tion was further aggravated after AFB1 exposure in these HBx‐ex‐
pressing HepG2‐Tet‐ON‐HBx cells (Figure 2A,B). Mitochondrial 
fragmentation could be results of activated fission, suppressed fu‐
sion or both.25 Figure 2C,D showed that combined exposure to HBx 
and AFB1 induced an accumulation of p‐Drp1Ser616, one of the main 
proteins implicated in mitochondrial fission, in the mitochondria. This 
result was consistent with the western blot analysis that the protein 
expression of p‐Drp1Ser616 was increased in the mitochondrial frac‐
tions in DOX‐induced and AFB1‐treated HepG2‐Tet‐ON‐HBx cells 
(Figure 2E). Moreover, increased p‐Drp1Ser616 was also observed 
in other HBx and AFB1 co‐exposed hepatic cell lines, including 
HepG2.2.15 and differentiated HepaRG cells (Figure 2F,G). In con‐
trast to p‐Drp1Ser616, decreased expression of mitochondrial fusion 
protein mitofusin 1 and 2 (Mfn1 and Mfn2) was observed in HBx‐
expressing HepG2‐Tet‐ON‐HBx, HepG2.2.15, and differentiated 
HepaRG cells compared with corresponding controls (Figure 2E‐G). 
Moreover, AFB1 aggravated down‐regulation of Mfn1 and Mfn2 in‐
duced by HBx in these cells (Figure 2E‐G). In line with the in vitro 
experiments, exposure to AFB1 increased expression of p‐Drp1Ser616 
in both the liver of HBV‐Tg mice in vivo (Figure 2H,I) and PHHs from 
the livers of HLC mice with HBV infection ex vivo (Figure 2J), com‐
pared with corresponding controls. Decreased protein expression 
of carnitine palmitoyltransferase 1A (CPT1A) (Figure 2I,J), a primary 
rate‐limiting enzyme involved in mitochondrial FA β‐oxidation, oc‐
curred in parallel to the changes in mitochondrial dynamics. To fur‐
ther demonstrate that inhibition of CPT1A observed in HBx and 
AFB1‐exposed hepatocytes were mediated through altering Drp1‐
dependent mitochondrial dynamics, Drp1 was knocked down by siD‐
NM1L in differentiated HepaRG cells. Figure 2K,L showed that HBx 
and AFB1 co‐treatment failed to decrease CPT1A, Mfn1 and Mfn2, 
and to increase LDs when Drp1 was knocked down in differentiated 
HepaRG cells. As a result, Drp1‐associated mitochondrial dynamics 
abnormalities were involved in the suppressing of CPT1A during HBx 
and AFB1 co‐treatment‐induced LDs accumulation.
3.3 | COX‐2 regulated hepatic steatosis via 
mitochondrial dynamics remodeling in AFB1‐treated 
HBV‐Tg mice and HBx‐expressing hepatocytes
The role of COX‐2 in HBV‐related mitochondrial dynamics abnormal‐
ities was investigated. Genomic expression data set of HBV infected 
patient were employed to explore the relationship among expression 
of DNM1L, PTGS2 and HBV infection. Figure 3A,B showed that 
higher mRNA levels of DNM1L and PTGS2 was shown in the liver bi‐
opsy of HBV‐infected patient tissues (n = 122) compared with those 
in normal tissues (n = 6). Moreover, there was a significant correlation 
(r = 0.5116, P < 0.0001) between expression of DNM1L and PTGS2 in 
these samples (Figure 3C). Figure 3D,E showed that protein levels 
of Cox‐2 was increased in the liver of both AFB1‐exposed mice and 
HBV‐Tg mice compared with corresponding control mice, and the 
highest level was shown in the liver of AFB1‐exposed HBV‐Tg mice 
in vivo. In addition, significantly elevated COX‐2 was observed in 
AFB1‐exposed PHHs from the livers of HLC mice with HBV infection 
ex vivo (Figure 3F) and human hepatic cell lines following single and 
combined treatment of HBx and AFB1 in vitro (Figure 3G, Supporting 
information: Figure S2). Importantly, HBx and AFB1‐stimulated up‐
regulation of Drp1 and down‐regulation of CPT1A, Mfn1 and Mfn2 
were ameliorated when differentiated HepaRG cells were trans‐
fected with siPTGS2 (Figure 3H), consequently increasing LDs depos‐
its (Figure 3I). Besides siRNA, CRISPR/Cas9 gene‐editing technique 
was applied to generate COX‐2‐deficient HepG2‐Cas9‐PTGS2 cell 
line. Figure 3J,K confirmed that these inducible effects of HBx and 
AFB1 on mitochondrial dynamics imbalance and subsequently LDs 
accumulation were indeed abolished in HepG2‐Cas9‐PTGS2 cells. 
Taken together, COX‐2 was critical in mediating Drp1‐dependent mi‐
tochondrial fission during HBx and AFB1‐induced hepatic steatosis.
3.4 | HBx and AFB1‐induced steatosis was 
associated with the formation of necrosome
Mitochondrial dynamics imbalance has been reported to be in‐
volved in cell apoptosis, necroptosis, or other regulatory cell death. 
Figure 4A‐C showed that the protein expression of both RIP1 and 
RIP3, as well as phosphorylation of MLKL (p‐MLKL), a substrate of 
RIP kinase, were increased in the liver of AFB1‐exposed HBV‐Tg mice 
and AFB1‐exposed PHHs from mice with HBV infection, compared 
with unexposed corresponding controls. Consistent with the results 
shown in vivo and ex vivo, up‐regulation of the RIP3‐MLKL signal‐
ling cascades were observed in three AFB1‐exposed hepatocytes 
with HBx expression (Figure 4D‐F). Interestingly, Figure 4G showed 
that dysregulation of Drp1, Mfn1 and Mfn2 in response to HBx and 
AFB1 in differentiated HepaRG cells were reversed by MLKL in‐
hibitor necrosulfonamide (NSA). What's more, pretreatment of NSA 
(Figure 4H) or necrostatin‐1 (Nec‐1) (Figure 4I), an inhibitor of RIP1, 
also counteracted the increase in LDs in the HBx and AFB1 co‐ex‐
posed differentiated HepaRG cells. HBx and AFB1‐induced necro‐
some formation was responsible, at least in part, for the hepatic 
mitochondrial dynamics imbalance and related LDs accumulation.
3.5 | HBx and AFB1‐induced formation of 
necrosome depended on the COX‐2
We showed that HBx and AFB1‐triggerd mitochondrial dynamics ab‐
normalities could be downstream of COX‐2 and necrosome formation 
on mitochondria, but whether COX‐2 was involved in the formation 
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of necrosome remained unclear. Figure 5A showed that the mRNA 
expression of MLKL was higher in the liver of HBV‐infected patient 
than those in normal tissues, and moreover, the expression of MLKL 
was positively correlated with PTGS2 (Figure 5B), suggesting that 
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COX‐2 might have a role in regulation of necrosome formation. 
As expected, inhibition of COX‐2 expression by the CRISPR/Cas9 
system decreased the HBx and AFB1‐stimulated up‐regulation 
of RIP1, RIP3 and p‐MLKL (Figure 5C). The level of RIP3 in mito‐
chondrial was also decreased when COX‐2 was inhibited in HBx and 
AFB1 co‐treated HepG2 cells (Figure 5D) and HepG2‐Tet‐ON‐HBx 
cells (Figure 5E,F). More importantly, PLA showed that combined 
exposure to HBx and AFB1 significantly increased the interaction 
between COX‐2 and RIP3 in HepG2‐Tet‐ON‐HBx cells, whereas 
the interaction was reduced when COX‐2 was inhibited by siPTGS2 
(Figure 5G). Furthermore, co‐treatment of HepG2‐Tet‐ON‐HBx cells 
with HBx and AFB1 promoted binding of RIP3 to COX‐2 and MLKL, 
which suggested that HBx and AFB1 triggered the formation of a 
COX‐2‐RIP3‐MLKL complex on mitochondria. When COX‐2 was 
inhibited, the interaction between RIP3 and MLKL was weakened 
(Figure 5H), subsequently blocked the necrosome formation and 
protected hepatocytes from necroptosis. Therefore, HBx and AFB1 
mediated COX‐2 up‐regulation was required for MLKL to be re‐
cruited to RIP3 for subsequent execution of necroptosis, and COX‐2 
could serve as a potential therapeutic target for necrotic cell death‐
associated hepatic steatosis.
4  | DISCUSSION
HBV is a small hepatotropic DNA virus responsible for some chronic 
liver diseases in humans, but the role of HBV infection in the fatty 
liver diseases remains controversial.3,4,26 In this study, together with 
previous animals and cellular data,2,26 the ectopic fat storage was 
consistently observed in the liver of HBV‐Tg mice. Moreover, we fur‐
ther demonstrated that the amount of LDs was increased in multi‐
ple HBx‐expressing human hepatic cell lines including HepG2.2.15, 
HepG2‐Tet‐ON‐HBx and differentiated HepaRG cells. Given that 
single use of systems based on liver cell lines existed some inevita‐
ble limitations, HLC mice were introduced and the consistent results 
obtained in PHHs from HBV‐infected HLC mice strengthened the 
evidence linking HBV infection with hepatic steatosis. In addition, 
this study showed an effect of AFB1 on exacerbation of HBx‐related 
hepatic steatosis. AFB1 alone has been suggested as a risk factor for 
NAFLD.6,27 Human are exposed to AFB1 mainly through contami‐
nated food, especially corns, peanuts and rice. After ingestion, AFB1 
is activated by cytochrome P450 within the liver microsome system 
to produce large amount of toxic metabolite.28,29 HBV infection has 
been reported to facilitate metabolism and bioactivation of AFB1 in 
the liver via the transactivation of pregnane X receptor (PXR) and 
induction in CYP3A4.30,31 Moreover, HBV originating from chronic 
hepatitis or the virus itself could exacerbate host response to AFB1 
and down‐regulated detoxification‐related proteins,32‐34 mak‐
ing HBV‐infected hepatocytes more susceptible to AFB1 toxicity. 
Instead, exposure to AFB1 would also exacerbate and accelerate 
the disease progression of HBV infection, perhaps via affecting sus‐
ceptibility to infection or viral replication.35 In tropical and humid 
area such as Southern China, many people are chronically infected 
with HBV while also exposing AFB1 in their diet.7 Individuals with 
HBV infection were much more susceptible to AFB1‐associated 
HCC risk compared with those without these aetiological factors.36 
Consistent with the combined role of HBV infection and AFB1 ex‐
posure in hepatocarcinogenesis, this study highlighted the effects 
of acute co‐exposure to HBx and AFB1 on hepatic steatosis. These 
results provided important clues and scientific bases for further 
population‐based studies investigating whether AFB1 exposure 
combined with HBV infection would increase the risk of NAFLD. 
The details of how AFB1 interact with HBx in vivo are still needed 
to further explore.
The mechanism of the combinative effects of HBx and AFB1 on 
hepatic lipid metabolism is complex. There have been studies sug‐
gesting that the dysregulation of genes involved in de novo lipogene‐
sis, such as sterol regulatory element binding transcription factor 1c 
(SREBP1C), liver X receptors (LXRs), fatty acid synthase (FASN) and 
peroxisome proliferator activated receptor gamma (PPARγ), were 
involved in HBV‐induced hepatic steatosis.2 Apart from increasing 
lipogenesis, HBx up‐regulated fatty acid binding protein 1 (FABP1), 
a gene responsible intracellular FA transport and utilization.3 In ad‐
dition, mitochondrial dysfunction also has been detected in liver 
F I G U R E  2   Drp1‐dependent mitochondrial dynamics abnormalities regulated hepatitis B virus X protein (HBx) and aflatoxin B1 (AFB1)‐
induced hepatic steatosis. A, Representative immunofluorescence images of mitochondria in HepG2‐Tet‐ON‐HBx cells stained with 
MitoTracker. Scale bar represents 10 μm. B, Quantification of mitochondrial fragmentation counts analysed by Image Pro Plus version 
6.0 software. C, Representative images of the immunofluorescence co‐staining for p‐Drp1Ser616 (Green) and MitoTracker (Red) in HepG2‐
Tet‐ON‐HBx cells. Nucleus was stained with DAPI (blue). Scale bar represents 10 μm. D, Pearson’s correlation for the co‐localization of 
p‐Drp1Ser616 with mitochondria. E, The expression of mitochondrial dynamics‐related proteins in mitochondrial and cytosolic fractions of 
HepG2‐Tet‐ON‐HBx cells. GAPDH and COXIV were served as the loading control of cytosolic and mitochondrial fraction, respectively. F and 
G, The protein expression of mitochondrial dynamics‐related proteins in whole cell lysates of HepG2.2.15 cells (F), and HepaRG cells (G). H, 
Immunohistochemical staining of p‐Drp1Ser616 in the liver of WT and HBV‐Tg mice treated with AFB1 or vehicle. Scale bar represents 50 μm. 
I, The protein expression of p‐Drp1Ser616, Drp1 and Cpt1a in the liver of WT and HBV‐Tg mice. J, The protein expression of p‐Drp1Ser616, Drp1 
and CPT1A in PHHs from livers of HLC mice. K and L, The differentiated HepaRG cells were transfected with siNC or siDNM1L (50 nmol/L) 
for 12 h before AFB1 treatment and HBx expression. K, The protein expression of mitochondrial dynamics‐related proteins and CPT1A 
in differentiated HepaRG cells. L, Representative images and spectrophotometric quantification of lipid droplets (LDs) in differentiated 
HepaRG cells. Scale bar represents 10 μm. For western blot analysis, GAPDH served as a loading control. Data were represented by 
mean ± SD. n = 3. *P < 0.05 compared with unexposed HepG2‐Tet‐ON‐HBx cells. #P < 0.05 compared with DOX‐treated HepG2‐Tet‐ON‐
HBx cells. †P < 0.05 compared with AFB1‐exposed HepG2‐Tet‐ON‐HBx cells. ^P < 0.05 compared with unexposed differentiated HepaRG 
cells transfected with siNC. &P < 0.05 compared with HBx and AFB1‐cotreated differentiated HepaRG cells transfected with siNC
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tissues from patients with chronic liver diseases.37 The imbalance 
of fusion and fission homoeostasis is one of the important deter‐
minant of mitochondrial function.38 In this study, co‐exposure to 
HBx and AFB1 increased mitochondrial fragmentation in HepG2‐
Tet‐ON‐HBx cells, implying changes in mitochondrial dynamics.25 
Indeed, p‐Drp1Ser616 responsible for the activation of Drp1‐mediated 
mitochondrial fission were increased in the HBx and AFB1 co‐
treated hepatocytes in vitro and ex vivo, as well as the liver of AFB1‐
exposed HBV‐Tg mice in vivo. Co‐exposure to HBx and AFB1 also led 
to a coordinate reduction in the expression of fusion protein Mfn2 
in hepatocytes. Mitochondrial dysfunction could impair activity of 
FA β‐oxidation. Although it was reported that single HBx expression 
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F I G U R E  3   COX‐2 regulated hepatitis B virus X protein (HBx) and aflatoxin B1 (AFB1)‐induced hepatic steatosis. A and B, In a cohort 
from GEO database (accession no. GSE83148), the mRNA level of DNM1L (A) and PTGS2 (B) was analysed in the liver tissues from CHB 
patients (n = 122) and normal participants (n = 6). C, Pearson’s correlation analysis between the mRNA expression of DNM1L and PTGS2. 
D, Immunohistochemical staining of Cox‐2 in the liver of WT and HBV‐Tg mice treated with AFB1 or vehicle. Scale bar represents 50 μm. 
E, The protein levels of Cox‐2 in the liver of WT and HBV‐Tg mice. F, The protein levels of COX‐2 in the liver of PHHs from livers of HLC 
mice. G, The mRNA and protein levels of COX‐2 in differentiated HepaRG cells. H and I, Differentiated HepaRG cells were transfected with 
siNC or siPTGS2 (50 nmol/L) for 12 h before AFB1 treatment and HBx expression. H, The expression of mitochondrial dynamics‐related 
proteins and CPT1A in differentiated HepaRG cells. I, Representative images and spectrophotometric quantification of lipid droplets (LDs) 
in differentiated HepaRG cells. Scale bar represents 10 μm. J and K, COX‐2‐deficient HepG2 cells were generated via CRISPR/Cas9 system. 
The HepG2‐Cas9‐NC and HepG2‐Cas9‐PTGS2 cells were transfected with pcDNA3.1‐HBX (1 μg/mL) to induce HBx expression and the 
cells were exposed to 1 μmol/L of AFB1 or DMSO for 48 h. J, The expression of mitochondrial dynamics‐related proteins. K, Representative 
images and spectrophotometric quantification of LDs. Scale bar represents 10 μm. For Western blot, GAPDH was served as a loading 
control, and for mRNA expression, ACTB was served as a loading control. Data were represented by mean ± SD. n = 3. *P < 0.05 compared 
with unexposed differentiated HepaRG cells. #P < 0.05 compared with HBx‐expressing differentiated HepaRG cells. †P < 0.05 compared 
with AFB1‐exposed differentiated HepaRG cells. ^P < 0.05 compared with HepG2‐Cas9‐NC cells. &P < 0.05 compared with HBx and AFB1‐
cotreated HepG2‐Cas9‐NC cells
F I G U R E  4   Hepatitis B virus X protein (HBx) and aflatoxin B1 (AFB1)‐induced hepatic steatosis was associated with necrosome formation. 
A, Immunohistochemical staining of Rip3 in the liver of WT and HBV‐Tg mice treated with AFB1 or vehicle. Scale bar represents 50 μm. 
B, The protein expression of the necrosome components in the liver of WT and HBV‐Tg mice. C, The protein levels of the necrosome 
components in PHHs from livers of HLC mice. D‐F, The protein levels of the necrosome components in HepG2.2.15 cells (D), HepG2‐Tet‐
ON‐HBx cells (E), and differentiated HepaRG cells (F). G‐I, Differentiated HepaRG cells were pretreated with 1 μmol/L NSA (G and H) or 
15 μmol/L Nec‐1 (I) for 12 h before HBx and AFB1 treatment. G, The expression of mitochondrial dynamics‐related proteins in differentiated 
HepaRG cells with NSA treatment. H and I Representative images of lipid droplets (LDs) in differentiated HepaRG cells with NSA (H) and 
Nec‐1 (I) treatment. Scale bar represents 10 μm. For western blot analysis, GAPDH was served as a loading control
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F I G U R E  5   Hepatitis B virus X protein (HBx) and aflatoxin B1 (AFB1)‐induced formation of necrosome depended on the mitochondrial 
COX‐2 expression. A, In a cohort from GEO database (accession no. GSE83148), the mRNA level of MLKL was analysed in the liver tissues 
from CHB patients (n = 122) and in normal participants (n = 6). B, Pearson’s correlation analysis between the mRNA expression levels of 
PTGS2 and MLKL. C, The protein expression of COX‐2 and the necrosome components in HepG2‐Cas9‐NC and HepG2‐Cas9‐PTGS2 cells. 
D, The protein expression of RIP3 and COX‐2 in mitochondrial and cytosolic fractions of HepG2‐Cas9‐NC and HepG2‐Cas9‐PTGS2 cells. 
E‐H, HepG2‐Tet‐ON‐HBx cells were transfected with siNC or siPTGS2 (50 nmol/L) for 12 h before DOX stimulation and AFB1 treatment. 
E and F, Representative images (E) and spectrophotometric quantification (F) of the immunofluorescence co‐staining for TOM20 (Red) and 
RIP3 (Green) in HepG2‐Tet‐ON‐HBx cells. G, The interaction of COX‐2 with RIP3 was detected by proximity ligation assay (PLA). Interaction 
events were shown as red foci. Quantification of COX‐2/RIP3 interaction events were shown on the right side of the bar. H, Immunoblot 
analysis of the interaction of RIP3 with COX‐2 or p‐MLKL in immunoprecipitates of HepG2‐Tet‐ON‐HBx cells. GAPDH and COXIV were 
served as the loading control of cytosolic and mitochondrial fraction, respectively. Scale bar represents 10 μm. Data were represented by 
mean ± SD. n = 3. *P < 0.05 compared with untreated HepG2‐Tet‐ON‐HBx cells transfected with siNC. #P < 0.05 compared with DOX and 
AFB1‐cotreated HepG2‐Tet‐ON‐HBx cells transfected with siNC
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turned out to have no effect on PPARα involved in FA β‐oxidation,38 
in our study, we found that the protein level of CPT1A, a primary 
rate‐limiting enzyme involved in mitochondrial FA β‐oxidation and 
metabolism was down‐regulated in three distinct HBx expressing 
hepatocytes treated with AFB1. Moreover, the expression of CPT1A 
was decreased in the AFB1‐exposed PHHs from HBV‐infected HLC 
mice ex vivo and the liver of HBV‐Tg mice in vivo. Down‐regulation 
of CPT1A would reduce FA transport into the mitochondrial matrix 
from the cytoplasm and force FA to LDs for storage in hepatocytes. 
As a result, co‐exposure to AFB1 and HBx decreased CPT1A, which 
could exacerbate hepatosis in the hepatocytes. Most importantly, 
knocking down of Drp1 with siDNM1L genetic intervention amelio‐
rated the reduction in CPT1A and the abnormal LDs accumulation 
in HBx and AFB1 co‐exposed differentiated HepaRG cells, further 
highlighting that the shift of the mitochondrial dynamics toward fis‐
sion mediated by Drp1 was involved in HBx and AFB1 co‐exposure‐
triggered hepatic steatosis.
For the question of how HBx and AFB1 activated Drp1, our 
previous investigation into mechanisms of the stemness of naso‐
pharyngeal carcinoma showed that COX‐2 increased the activation 
of Drp1 by recruiting the mitochondrial translocation of p53.15 
COX‐2 is a key enzyme in the synthesis of prostaglandins and its 
expression has been reported to be widely up‐regulated in multiple 
human cancers, including colorectal cancers,39 prostate cancers,40 
gastric cancers41 and pancreatic cancers,42 etc, In line with the high 
expression identified in cancer pathogenesis, this study found that 
transcription of PTGS2 gene was up‐regulated in a GEO cohort 
of HBV‐infected patients. Moreover, both the mRNA and protein 
level of COX‐2 were increased in the HBx and AFB1 co‐exposed 
hepatocytes in vitro, the HBV‐infected and AFB1‐exposed PHHs 
in HLC mice ex vivo, and the liver of AFB1‐treated HBV‐Tg mice in 
vivo. It was reported that the expression of COX‐2 was extremely 
low in normal liver,43 but was increased under pathological condi‐
tions such as acute liver failure,44 hepatic fibrosis and cirrhosis,45 
and hepatocarcinogenesis.43 To date, the implication of COX‐2 in 
hepatic steatosis remains controversial. It was reported that COX‐2 
transgenetic mice on a high‐fat diet exhibited reduction in he‐
patic steatosis and enhancement of insulin sensitivity and glucose 
tolerance compared with corresponding wild type mice.46 But in 
contrast, expression of COX‐2 was reported to be significantly in‐
creased in human hepatic biopsy specimens of patients with NAFLD 
and the up‐regulation of COX‐2 contributed to protection against 
insulin resistance.17 This finding seemed reasonable since consti‐
tutive expression of COX‐2 in hepatocytes could activate proteins 
F I G U R E  6   Schematic diagram of the 
signalling pathways involved in hepatitis 
B virus X protein (HBx) and aflatoxin B1 
(AFB1) co‐exposure‐induced hepatic 
steatosis. We showed that HBx combined 
with AFB1 exposure increased amount 
of lipid droplets (LDs) in the PHHs from 
HBV‐infected HLC ex vivo, the liver of 
HBV‐Tg mice in vivo, as well as multiple 
HBx‐expressing human hepatic cell lines 
in vitro. In the hepatocytes, AFB1 and 
HBx increased the expression of COX‐2 
in mitochondria and thereby promoting 
the co‐location of COX‐2 and RIP3‐MLKL 
necrosome on mitochondria. Moreover, 
AFB1 and HBx up‐regulated COX‐2 to 
trigger Drp‐1‐mediated mitochondrial 
fragmentation and dysfunction in the 
hepatocytes. Necrosome formation and 
mitochondrial dynamics disorder finally 
contributing to the LDs accumulation in 
the hepatocytes
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involved in cell survival, such as serine/threonine kinase (AKT) and 
AMP‐activated protein kinase (AMPK), thereby increasing hepatic 
insulin signalling and preserving insulin resistance during NAFLD.47 
Conversely, blocking COX‐2 activity with the selective inhibitors, 
celecoxib or nimesulide, ameliorated steatohepatitis and hyperlip‐
idaemia in transgenic mouse model overexpressing the α1 subunit 
of AMPK.48 Our study supported the facilitating role of COX‐2 in 
NAFLD by showing that co‐exposure of HBx and AFB1 failed to ac‐
tivate mitochondrial fission protein Drp1 and down‐regulate CPT1A 
implicated in FA β‐oxidation when COX‐2 was knocked down by 
siPTGS2 or CRISPR/Cas9 system (Supporting information: Figure 
S2), which occurred in parallel to the reduction in LDs.
Drp1‐associated mitochondrial fragmentation is a required 
step for execution of apoptosis and necroptosis.49,50 In this study, 
combined exposure to AFB1 decreased cell viability in all three 
HBx‐expressing hepatocytes (Supporting information: Figure 
S3). Co‐treatment of HBx and AFB1 with Nec‐1 offset the sup‐
pression action of HBx and AFB1 on cell viability, implying that 
such detrimental effects may be related to necroptosis. Indeed, 
HBx and AFB1 co‐exposure increased the expression of RIP1 and 
RIP3, as well as the p‐MLKL in hepatocytes. Higher expression of 
MLKL in HBV‐infected patient was correlated with the increased 
expression of PTGS2 in these clinical samples. HBx and AFB1‐in‐
duced up‐regulation of RIP3 in mitochondrial of HepG2 cells was 
abrogated when COX‐2 were knocked down by CRISPR/Cas9 
system. Therefore, COX‐2 could recruit RIP3 to mitochondria. 
Most importantly, we verified that RIP3 was in close proximity 
with COX‐2 on mitochondria in HBx and AFB1‐exposed HepG2‐
Tet‐ON‐HBx cells and HepG2 cells (Supporting information: 
Figure S4). Moreover, co‐precipitated p‐MLKL and RIP3 were 
significantly reduced after COX‐2 was decreased by siPTGS2. 
These data elucidated that knockdown of COX‐2 protected HBx 
and AFB1 co‐exposed hepatocytes from necroptosis via sup‐
pressing necrosome formation on mitochondria. In addition, we 
further confirmed that Drp1‐related mitochondrial dynamics ab‐
normalities were also the downstream mediators of necrosome 
formation during the process of LDs accumulation in HBx and 
AFB1‐co‐exposed hepatocytes. This is the first study reporting 
the pivotal role of COX‐2 in regulation of necrosome formation 
and Drp1‐mediated mitochondrial fragmentation during HBx 
and AFB1‐induced hepatic steatosis. Therefore, pharmacological 
modification and genetic intervention targeted at COX‐2 activ‐
ity seems to be a potential therapeutic strategy counteracting 
HBV infection and/or AFB1 exposure‐related hepatic steatosis, 
as well as hepatic diseases associated with necrotic cell death.
Taken together, exposure to AFB1, combined with HBx, increased 
risk of hepatic steatosis. Owing to the up‐regulation of COX‐2, co‐
exposure to HBx and AFB1 promoted the formation of RIP3‐MLKL 
necrosome and induced Drp‐1‐mediated mitochondrial fragmenta‐
tion and dysfunction in the hepatocytes, finally contributing to the 
LDs accumulation (Figure 6). COX‐2 could be a target molecular for 
developing agents for prevention and therapy to the inducible mito‐
chondria‐associated hepatic necroptosis and/or NAFLD.
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